FP Instruments Spółka z Ograniczoną Odpowiedzialnością (KRS 0000356201, NIP 6312611610) is a Polish company, headquartered in Gliwice, Śląskie voivodeship. FP INSTRUMENTS operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since May 17, 2010. FP INSTRUMENTS's most recently reported net revenue was 458.5 K PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - FP Instruments
Identity
- Name
- FP Instruments Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- May 17, 2010
- Registry status as of
- June 10, 2026
- Latest entry
- June 10, 2026
- Founding act
- 11.02.2010R. NOTARIUSZ JOANNA WARZECHA, KANCELARIA NOTARIALNA W GLIWICACH, AKT NOTARIALNY REP. A NR 1538/2010
Articles of association history (3)
- February 11, 2010: 11.02.2010R. NOTARIUSZ JOANNA WARZECHA, KANCELARIA NOTARIALNA W GLIWICACH, AKT NOTARIALNY REP. A NR 1538/2010
- March 6, 2019: 06.03.2019 R., NOTARIUSZ ZUZANNA WOJTASZEK-BAŁAZIŃSKA, KANCELARIA NOTARIALNA W KATOWICACH, REP. A NR 963/2019 - ZMIENIONO: §7 UST.1, §8, §10 UST.1, §12 UST.2, §12 UST.4 UMOWY SPÓŁKI
- May 22, 2019: 22.05.2019 R. - REP.A NR 2644/2019, NOTARIUSZ KINGA BEDNARZ, KANCELARIA NOTARIALNA W KATOWICACH ZMIENIONO: §7 UST.1, §8
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. BOJKOWSKA, 37A, 44-100, GLIWICE, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- GLIWICE
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-51152-41297-AECSF-25
Risk and payment profile - FP Instruments
Credibility rating
44.5 / 100
Average credibility
Insolvency risk
Very low
Elevated threat
Closure risk
27
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
5
5/16 yrs
Board changes
3
3/16 yrs
PKD changes
1
1/16 yrs
Name changes
0
0/16 yrs
Data from 16 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: D (45/100)
Trend: improving (+7.4 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2018–2024
Current: 12.9 K PLN
Safe: 3.9 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - FP Instruments
Founded
May 17, 2010
16 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
GLIWICE
ŚLĄSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
70.0 K PLN
1,400 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
7 years
2018–2024 · profitable: 4/7
Registry entries
44
latest: June 10, 2026
Risk signals
Revenue
458.5 K PLN
2024
Net profit
-237.4 K PLN
2024
Assets
1.6 M PLN
2024
Equity
1.6 M PLN
2024
EBITDA
N/A
2024
no depreciation data
Valuation
721.4 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - FP Instruments.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
